Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07388524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
MinorTrial sites expanded: 83 → 96 locationsTrial sites expanded: 72 → 83 locationsShow 1 more changeShow less
Trial sites expanded: 72 → 83 locations
MinorStudy sites: 72 to 83
MinorStudy sites: 70 to 72
MinorTrial sites expanded: 63 → 70 locationsSecondary endpoints: details revised at 6 of 6 entriesShow 1 more changeShow less
Secondary endpoints: details revised at 6 of 6 entries
MinorTrial sites expanded: 59 → 63 locationsv71
MinorSite details revised at 4 of 59 sitesv70
MinorSite details revised at 4 of 59 sitesv69
MinorTrial sites expanded: 55 → 59 locationsv68
MinorTrial sites expanded: 51 → 55 locationsv67
MinorTrial sites expanded: 44 → 49 locationsv66
MinorTrial sites expanded: 36 → 43 locationsv65
MinorStudy sites: 43 to 44v64
MinorStudy sites: 36 to 43v63
MinorStudy sites: 34 to 36v62
MinorStudy sites: 33 to 34v61
MinorTrial sites expanded: 25 → 33 locationsv60
MinorTrial sites expanded: 20 → 25 locationsv59
MinorTrial sites expanded: 15 → 18 locationsv58
MinorStudy sites: 15 to 18v57
MinorStudy sites: 14 to 15v56
MinorStudy sites: 13 to 14v55
MinorStudy sites: 11 to 13v54
MinorStudy sites: 10 to 11v53
MinorTrial sites expanded: 5 → 10 locationsTrial sites expanded: 2 → 5 locationsv52Show 1 more changeShow less
Trial sites expanded: 2 → 5 locations
MinorStudy sites: 2 to 5v51
MinorStudy sites: 3 to 2v50
MinorStudy sites: 1 to 3v49
NotablePrimary and study completion pushed from Sep 30, 2029 to Sep 30, 2032Recruitment opened · Start date: Jun 5, 2026 to Mar 2, 2027 · Study sites: 0 to 1v48Show 3 more changesShow less
Recruitment opened
Start date: Jun 5, 2026 to Mar 2, 2027
Study sites: 0 to 1
MinorRe-verified, no change to tracked fieldsv47
NotableStart date: Apr 9, 2026 to Jun 5, 2026v46
Minor19 versionsRe-verified since Mar 13, 2026, no change to tracked fieldsv27-v45
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.